Studies have also indicated that PI3K activation serves as an unfavorable prognostic factor for HER2‐positive GC [52, 53], and the PI3K/Akt/mTOR pathway acts as a predictive factor for HER2‐positive advanced GC treatment with trastuzumab [14]. This evidence concerns the gene ERBB2 and gastric cancer.